NanoDx, SkyWater develop nanoscale tech for COVID testing

By LabPulse.com staff writers

October 6, 2021 -- NanoDx and SkyWater are partnering to further develop and bring to market nanoscale sensor technology for rapid COVID-19, traumatic brain injury, sepsis, and stroke testing.

The nanosensor features wires that find and quantify biomarkers and infections in the blood; the technology is based on research that came out of Harvard University, according to NanoDx.

NanoDx and SkyWater plan to pursue an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) specifically for a two-minute, point-of-care COVID-19 test, NanoDx said.

NanoDx inks deal with IBM, seeks EUA for COVID-19 test
NanoDx announced that it has signed a licensing deal with IBM Research and will pursue an emergency use authorization (EUA) from the U.S. Food and Drug...

Copyright © 2021 LabPulse.com

Last Updated ls 10/6/2021 1:15:09 PM